| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ME Stock Overview
23andMe Holding Co. operates as a consumer genetics testing company.
23andMe Holding Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.12 |
| 52 Week High | US$13.68 |
| 52 Week Low | US$2.12 |
| Beta | 0 |
| 1 Month Change | 82.21% |
| 3 Month Change | 84.17% |
| 1 Year Change | -32.63% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.75% |
Recent News & Updates
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target
Shareholders will be ecstatic, with their stake up 34% over the past week following 23andMe Holding Co. 's ( NASDAQ:ME...
23andMe Q1 2023 Earnings Preview
23andMe (NASDAQ:ME) is scheduled to announce Q1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.16 (+36.0% Y/Y) and the consensus Revenue Estimate is $61.6M (+4.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
23andMe is a consumer-facing genetics testing company, one of the largest in terms of genetic databases. However, there are some glaring financial risks to consider if you want to invest in the company: slow test kit growth and profitability. New attempts to move towards drug development and primary care telehealth may drive revenues, it will continue to be unprofitable. For these reasons, I would recommend avoiding the company.
Shareholder Returns
| ME | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 40.7% | 2.3% | 3.2% |
| 1Y | -32.6% | 14.7% | -10.2% |
Return vs Industry: ME underperformed the US Healthcare industry which returned 14.7% over the past year.
Return vs Market: ME underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| ME volatility | |
|---|---|
| ME Average Weekly Movement | 12.4% |
| Healthcare Industry Average Movement | 8.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Anne Wojcicki | https://www.23andme.com |
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
23andMe Holding Co. Fundamentals Summary
| ME fundamental statistics | |
|---|---|
| Market Cap | US$2.31b |
| Earnings (TTM) | -US$265.00m |
| Revenue (TTM) | US$277.17m |
8.3x
P/S Ratio-8.7x
P/E RatioIs ME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ME income statement (TTM) | |
|---|---|
| Revenue | US$277.17m |
| Cost of Revenue | US$149.43m |
| Gross Profit | US$127.74m |
| Other Expenses | US$392.73m |
| Earnings | -US$265.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 46.09% |
| Net Profit Margin | -95.61% |
| Debt/Equity Ratio | 0% |
How did ME perform over the long term?
See historical performance and comparison